Logo Lucerna-Chem
+41 41 420 9636

Regulatory Status

Article Status


Ervogastat


Catalog Number Pack Size List Price* Promo Price* Quantity
HY-111620-5MG 5 mg 418,00 355,30 Add
HY-111620-10MMO 10 mM * 1 mL 460,00 391,00 Add
HY-111620-10MG 10 mg 691,00 587,40 Add
HY-111620-25MG 25 mg 1'210,00 1'028,50 Add
HY-111620-50MG 50 mg 1'870,00 1'589,50 Add
HY-111620-100MG 100 mg 2'749,00 2'336,70 Add

* CHF, excl. 7.7% VAT and shipping costs


Product Description

PF-06865571
Ervogastat (PF-06865571) is a potent and well-tolerated diacylglycerol acyltransferase 2 inhibitor (DGAT2i). Ervogastat alone reduces steatosis and hepatic triglyceride levels in non-alcoholic steatohepatitis (NASH). Ervogastat combination with Clesacostat (an acetyl CoA-carboxylase inhibitor (ACCi)) can be used for the research of NASH with liver fibrosis therapy.

Category Biochemicals
Supplier MedChem Express
Application Metabolism-sugar/lipid metabolism
Regulatory Status RUO
Format Solubility: DMSO : 125 mg/mL (306.81 mM; Need ultrasonic)
Grade Clinical information: No Development Reported
Molecular Formula C21H21N5O4
Molecular Weight 407.42
CAS-Number [2186700-33-2]
Storage Conditions Please store the product under the recommended conditions in the Certificate of Analysis.
Product Line Research
Tech. Data Sheet View datasheet
Link To Supplier http://www.medchemexpress.com
Material Safety Data Sheet Download PDF
Call us

Customer Support
T +41 41 420 96 36
F +41 41 420 96 56
info@lucerna-chem.ch

Business Hours
From Monday through Friday
08:00 – 12:00
13:00 – 17:00

Ask us

Technical Support
tech@lucerna-chem.ch

Business Development
business.dev@lucerna-chem.ch

Postal address
Lucerna-Chem AG
Abendweg 18
CH-6006 Luzern

Newsletter













If you have already subscribed to our newsletter and would like to update your details or cancel it, please click here.


© Copyright 2021 Lucerna-Chem AG, Switzerland